Many of us scientists, ethicists, and legal scholars are working on educational outreach to the public on the potential use of gene editing technologies like CRISPR to genetically modify human beings, but clearly there’s a long way to go and much more to do on this front. By the way, you may find this new […]
Public polling on human gene editing, moratorium Read More »
A decade ago I wrote an article in the journal Nature Biotechnology about the rise of a new gene editing technology called zinc finger nucleases (ZNF). It was one of those “drumbeat” discoveries: at the time, my sense was it would revolutionize how we deliver genes to cells and tissues, and profoundly change the way
Guest Post by Chris Scott–The Great CRISPR Controversy: What’s Next? Read More »
Last Thursday I participated in a meeting at Stanford Law School on human germline genetic modification hosted by Hank Greely (pictured at left), Professor of Law and Genetics at Stanford. The meeting was entitled, “Human Germline Modification: Medicine, Science, Ethics, and Law”. The panel included in addition to Hank and me, the following speakers: Marcy Darnovsky, Executive Director of
Stanford Human Germline Modification Meeting: Medicine, Science, Ethics, & Law Read More »
What is the “proper” amount of freedom of choice for patients in medicine? What if the treatments in question are experimental and come with their own baggage of associated risks, personal costs, and potential costs to society? More broadly, do patients have a fundamental right to medical choice? These questions seem particularly appropriate today on
Do Patients Have a Fundamental Right to Choice? Read More »
Statins have been hailed as some of the best drugs ever. Given the massive, deadly prevalence of cardiovascular disease, some have even semi-jokingly talked about putting these drugs in the water supply for public health. The growing evidence (e.g. this story) that statins might significantly aid in prevention, delayed progression, or even post-treatment delay of
Statins dilemma: heart & cancer benefits, but diabetes risk Read More »
Could Apple computers be getting into the genomics biz? In March, I was thinking it’d be fun to do an April Fool’s Day post. I wrote the following as a possible satire spoof piece title but never had a chance to do an actual post: iPhone 7 To Come With iPhone 7ATGC Version with Personal
Apple getting into the genomics biz? Read More »
Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy
Bioheart on the edge in 2015? Read More »
What is a GMO? I realized a few years ago that I really should know a lot more about the whole debate over genetically modified (GM) organisms (GMOs). What are the facts on GMOs? As a scientist who has for many years done amongst other things genetics research including making and studying so-called “knockout mice”
GMO: Why 3 Such Difficult Little Letters? Read More »
Later this May, I will attend and participate in Biotechnology and the Ethical Imagination (BEINGS 2015). This is an exciting and experimental summit that will focus on advances in cellular biotechnology – including both stem cell science and synthetic biology. The meeting is premised on the idea that the implications of increasing biotechnology power are
Biotechnology & the Ethical Imagination – A Preview of BEINGS summit Read More »
With more than 250 votes cast, Jennifer Doudna is leading by a decisive margin in a poll asking who deserves the patent for use of CRISPR-Cas9 as a tool. Feng Zhang got only just over half the votes of Doudna. Another take home message from this poll is that a sizable minority–almost one in five– said
Doudna most deserving of CRISPR Cas9 patent, says poll Read More »